Aliases:This biomarker is also known as:
- Type II HADH,
- mitochondrial RNase P subunit 2,
- 3-hydroxyacyl-CoA dehydrogenase type-2,
- EC 18.104.22.168,EC 22.214.171.124,
- 17-beta-HSD 10,
- Mitochondrial ribonuclease P protein 2,
- 3-hydroxyacyl-CoA dehydrogenase type II,
- mental retardation, X-linked, syndromic 10,
- short chain dehydrogenase/reductase family 5C, member 1,
- Endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
- 3-hydroxy-2-methylbutyryl-CoA dehydrogenase,
- 17-beta-hydroxysteroid dehydrogenase 10,
- AB-binding alcohol dehydrogenase,
- endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
- hydroxysteroid (17-beta) dehydrogenase 10,
- short chain type dehydrogenase/reductase XH98G2,
- amyloid-beta peptide binding alcohol dehydrogenase,
- short chain L-3-hydroxyacyl-CoA dehydrogenase type 2,
- Mitochondrial RNase P protein 2,
- mitochondrial ribonuclease P protein 2,
- Short-chain type dehydrogenase/reductase XH98G2,
- hydroxyacyl-Coenzyme A dehydrogenase, type II, hydroxyacyl-Coenzyme A dehydrogenase, type II,
HSD17B10, hydroxysteroid (17-beta) dehydrogenase 10, is a member of the short-chain dehydrogenase/reductase superfamily. HSD17B10 functions in mitochondrial tRNA maturation and catalyzes the oxidation of a wide variety of fatty acids, alcohols, and steroids. The protein is thought to play a role in the development of Alzheimer's disease. There are several alternatively spliced transcript variants, of which only two have been fully sequenced.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data is available.
HSD17B10 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.